Abstract
Linagliptin is a xanthine-based dipeptidyl peptidase (DPP)-4 inhibitor that is now available in numerous countries worldwide for the treatment of type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate further the mechanisms underlying the improvements in glycemic control observed with linagliptin. The effects of linagliptin on DPP-4, pharmacodynamic parameters, and glycemic control versus placebo were assessed in patients with inadequately controlled T2DM.
Original language | English |
---|---|
Journal | Diabetes Therapy |
Volume | 3 |
Issue number | 1 |
Pages (from-to) | 10 |
ISSN | 1869-6953 |
DOIs | |
Publication status | Published - Nov 2012 |